ENTRESTO Market

The Global ENTRESTO Market is estimated to be valued at USD 9.09 Bn in 2025 and is expected to reach USD 12.21 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 4.3% from 2025 to 2032. The Global ENTRESTO Market represents a pivotal segment within the cardiovascular therapeutics landscape, driven by the increasing prevalence of heart failure and the growing demand for innovative treatment solutions. ENTRESTO, a groundbreaking angiotensin receptor-neprilysin inhibitor (ARNI), has revolutionized heart failure management by combining sacubitril and valsartan in a single formulation, offering superior clinical outcomes compared to traditional ACE inhibitors.

This dual-mechanism medication works by simultaneously blocking the angiotensin II receptor and inhibiting neprilysin, an enzyme responsible for breaking down beneficial natriuretic peptides, thereby providing enhanced cardiovascular protection and improved patient outcomes. The market's expansion is significantly influenced by the rising geriatric population, sedentary lifestyles, and increasing incidence of comorbidities such as diabetes and hypertension that contribute to heart failure development. Healthcare systems worldwide are increasingly recognizing the clinical and economic value of ENTRESTO, as evidenced by its inclusion in major heart failure treatment guidelines and growing adoption across both developed and emerging markets.

Market Dynamics

The Global ENTRESTO Market is propelled by several compelling drivers that underscore its robust growth trajectory and market penetration potential. The primary driver stems from the escalating global burden of heart failure, affecting over 64 million people worldwide, coupled with aging demographics and lifestyle-related cardiovascular risk factors that continue to expand the patient population requiring advanced therapeutic interventions. Clinical evidence demonstrating ENTRESTO's superior efficacy in reducing cardiovascular mortality and heart failure hospitalizations compared to traditional treatments has accelerated physician adoption and guideline recommendations across major cardiology societies.

Healthcare economic pressures and value-based care initiatives further drive market growth as ENTRESTO demonstrates cost-effectiveness through reduced hospitalization rates and improved quality of life metrics. However, market expansion faces significant restraints including the medication's premium pricing compared to generic alternatives, which creates accessibility challenges in price-sensitive markets and limits adoption in healthcare systems with stringent budget constraints. Additionally, specific contraindications, including patients with a history of angioedema and certain ethnic populations with higher susceptibility to adverse reactions, restrict the eligible patient population. Complex titration requirements and potential drug interactions also pose prescribing challenges for healthcare providers. Despite these constraints, substantial opportunities emerge from expanding geographical presence in emerging markets, ongoing clinical trials investigating new indications including preserved ejection fraction heart failure, and potential combination therapies that could broaden therapeutic applications and market reach significantly.

Key Features of the Study

• This report provides an in-depth analysis of the global ENTRESTO market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global ENTRESTO market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key company covered as a part of this study include Novartis AG.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global ENTRESTO market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ENTRESTO market.

Market Segmentation

• Indication Insights (Revenue, USD Bn, 2020 - 2032)
• Chronic Heart Failure (CHF)
• Symptomatic heart failure with left ventricular systolic dysfunction in pediatric patients
• Dosage Forms Insights (Revenue, USD Bn, 2020 - 2032)
• Film-coated tablets
• Film-coated oral pellets within capsules
• Strength Insights (Revenue, USD Bn, 2020 - 2032)
• 24/26 mg
• 49/51 mg
• 97/103 mg
• 6 mg/6 mg
• 15 mg/16 mg
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
• Adults
• Pediatric
• Gender Insights (Revenue, USD Bn, 2020 - 2032)
• Male
• Female
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• End User Insights (Revenue, USD Bn, 2020 - 2032)
• Hospitals and Clinics
• Cardiology Centers
• Long-Term Care Facilities
• Ambulatory Care Centers
• Homecare Settings
• Others (Academic and Research Institutes, etc.)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Novartis AG

Show more